Results Presented From As1403 Phase I Biodistribution Study
London, UK plc (LSE:ASM, NASD-E:ASOM) (ots) - Antisoma announces that results from its phase I biodistribution study of AS1403 (formerly TheraFab) will be presented this weekend to the European Association of Nuclear Medicine meeting in Amsterdam by Dr Michael Garkavij, a leading investigator in the trial. AS1403 is a fragment of the monoclonal antibody HMFG1 linked to a radioactive isotope with cell-killing ...